Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Microgynon 30 is a combined oral contraceptive pill (COC) used primarily to prevent pregnancy. It contains two active ingredients, ethinylestradiol (an estrogen) and levonorgestrel (a progestogen), in doses of 30 micrograms and 150 micrograms per tablet, respectively. The mechanism of action involves three main effects: inhibition of ovulation by suppressing the release of an egg from the ovaries; thickening of cervical mucus to impede sperm penetration; and alteration of the endometrial lining to reduce the likelihood of implantation. When taken as directed—one tablet daily for 21 days followed by a seven-day break—Microgynon 30 is over 99% effective in clinical trials at preventing pregnancy. Additional benefits may include regulation and reduction in menstrual bleeding, relief from premenstrual symptoms, and decreased menstrual pain[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Microgynon 30.